Medtronic’s Asian Push and Portfolio Reshuffle Fail to Lift Stock from Its Lows

Medtronic is shedding complexity. After spinning off its diabetes division, the medical-device giant now operates three core pillars — cardiovascular, neuroscience, and surgical — each infused with artificial intelligence and robotics. The company, which employs more than 95,000 people globally, reports no fresh litigation or costly restructuring weighing on its balance sheet. This leaner structure is designed to compete in a medical-technology market projected to reach $9 billion by 2036, driven by wearable monitors and thrombectomy devices.

Two tactical moves this quarter underscore the strategy. On Thursday, Medtronic launched its PulseSelect ablation system in India, targeting an estimated seven million patients with atrial fibrillation. The system uses pulsed electric fields rather than extreme heat or cold, promising faster procedures and gentler tissue recovery. Separately, the acquisition of Scientia Vascular closed in mid-June, strengthening the company’s neurovascular portfolio. Management expects that deal to contribute to earnings after fiscal 2027. In Europe, Medtronic has also been expanding distribution of its heart monitors.

Yet the stock remains under pressure. Shares closed just above €69, down roughly 15% year to date. The recent low of €63.08, set in early June, has given way to a mild recovery, and the price has nudged above the 50-day moving average at €68.54 — a technical signal that buyers are stepping in, albeit cautiously.

Should investors sell immediately? Or is it worth buying Medtronic?

A note of caution came from inside the C-suite. Vice President Harry Skip Kiil recently sold 4,189 shares at $80.44 each, reducing his direct holdings by about 10%. Institutional investors, however, added to their positions during the quarter, indicating a split between insider sentiment and long-term fund conviction.

Wall Street remains divided. Most analysts rate Medtronic a moderate buy, though Truist advises holding, citing the need for stronger profit growth before turning more bullish. The international business is outperforming the U.S. home market, with diabetes products also contributing to the top line.

The PulseSelect rollout in India and the Scientia Vascular purchase are clear bets on emerging-market demand and specialized neurology. With no new legal overhangs and a streamlined corporate structure, Medtronic is positioning for the next cycle. The question is whether the stock will wait until fiscal 2027 for the payoff.